Hristov Alexandra (Orcid ID: 0000-0002-1836-6591)
Comfere Nneka (Orcid ID: 0000-0002-8001-2639)
Vidal Claudia (Orcid ID: 0000-0003-2672-4974)
Sundram Uma (Orcid ID: 0000-0002-0695-0045)

Kappa and Lambda Immunohistochemistry and In Situ Hybridization in the Evaluation of Atypical Cutaneous Lymphoid Infiltrates

Alexandra C. Hristov, M.D.[1], Nneka I. Comfere, M.D.[2], Claudia I. Vidal M.D., Ph.D.[3], and Uma Sundram M.D., Ph.D.[4]

[1]Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI

[2]Department of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

[3]Dermatology Center of Southern Indiana, Bloomington, IN

[4]Department of Pathology, Oakland University William Beaumont School of Medicine and Beaumont Health Systems, Royal Oak, MI

Key Words: kappa, lambda, immunohistochemistry, in situ hybridization, cutaneous, lymphoma

Running Title: Kappa and lambda expression in cutaneous lymphoma

The authors have no conflicts of interest to declare.

Corresponding Author:

Alexandra C. Hristov

Associate Professor

Departments of Pathology and Dermatology

2800 Plymouth Road, Building 35

Ann Arbor, MI 48109-2800

Phone: 734-764-4460

Fax: 734-764-4690

Email: ahristov@med.umich.edu

Abstract

Background: Atypical cutaneous lymphoid infiltrates are challenging lesions in dermatopathology. We present a summary of the literature regarding kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) in the evaluation of atypical cutaneous or mucosal lymphoid infiltrates.

Methods: Relevant articles from 1967-2018 in the English language were identified and summarized. In the absence of larger studies, case series of n≥3 were included.

Results: 63 articles assessing kappa and lambda IHC and/or ISH were identified. Most focused on marginal zone lymphomas. Other lymphomas included follicle center lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, plasmablastic lymphoma, multiple myeloma, monoclonal gammopathy of undetermined significance, and polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS). Non-neoplastic lesions included reactive lymphoid hyperplasia, cutaneous plasmacytosis, connective tissue disease, IgG4-related disease, acrodermatitis chronic atrophicans, Zoon's balanitis, dermatitides, and infiltrates around epithelial dysplasias/neoplasias.

Conclusion: Kappa and lambda IHC and ISH are useful tools in the evaluation of cutaneous B-cell lymphomas and plasma cell neoplasms. The literature supports that the detection of light chain restriction by IHC and ISH is one of the most useful findings in the differential diagnosis of reactive lymphoid hyperplasia versus B-cell lymphoma with plasmacytic differentiation.

Key Words: Kappa, lambda, immunohistochemistry, in situ hybridization, cutaneous, lymphoma

Introduction

Atypical cutaneous lymphoid infiltrates are diagnostically challenging lesions. They often require a combination of clinical, histopathologic, immunophenotypic and genetic features to arrive at an accurate diagnosis. Each of these features include pitfalls in interpretation and application, as reactive processes can mimic lymphomas both clinically and histopathologically and may also include a clonal B cell and/or T cell population. Kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) are useful tools in the evaluation of cutaneous B-cell lymphomas and plasma cells neoplasms. These studies target kappa or lambda light chains in plasma cells and, to a lesser extent, B cells. IHC for kappa and lambda on formalin-fixed, paraffin-embedded (FFPE) tissues is variably reported as cytoplasmic[1,2] or cytoplasmic and membranous[3,4] in the literature, and may depend on the antibody and technique used. In particular, enzyme digestion and heat-induced epitope retrieval techniques have been used to enhance the performance of IHC staining of neoplastic B cells in low grade B-cell lymphomas. In addition, the distinction between cytoplasmic and membranous staining may be difficult to discern.[1] Frozen section IHC analysis of kappa and lambda detects both cytoplasmic and membranous light chain.[1] ISH detects cytoplasmic mRNA. Flow cytometry (FC) may also be used to assess kappa and lambda ratios. FC routinely detects surface immunoglobulin and may also detect cytoplasmic immunoglobulin following a permeablization procedure.

Kappa and lambda expression is most abundant and therefore most easily detected in plasma cells, which lose surface immunoglobulin.[5,6] As such, only light chain restricted plasma cells or cells with lymphoplasmacytoid differentiation are best detected with IHC or ISH.[2,7,8] While the precise ratios of kappa and lambda expressing cells that signify monotypia have not been defined, when a marked predominance of kappa or a predominance of lambda light chain expression is identified, a clonal population is presumed (kappa:lambda of $\geq$8-10[8-15] or <0.1-0.3[8,10-18]). In contrast, non-neoplastic populations of B cells and plasma cells characteristically include a mixture of kappa and lambda-positive cells, often with a slight kappa predominance (kappa:lambda of approximately 1-4:1-2).[9,10,19-21] As part of the American Society of Dermatopathology (ASDP) Appropriate Use Committee (AUC) Task Force, lymphoproliferative subgroup, three practicing, board-certified dermatopathologists working in academic medical centers (N.C., A.H.) or a hybrid academic/private practice (U.S.), assessed the evidence-based, peer-reviewed literature from 1967 to 2018 on the utility of kappa and lambda IHC as compared to ISH in the evaluation of cutaneous B-cell lymphomas, plasma cell neoplasms and atypical cutaneous lymphoid infiltrates. This paper summarizes the literature for assessing light chain restriction in mucosal and cutaneous infiltrates by IHC and ISH and also briefly discusses other technologies.

Materials and Methods

Literature Review

PubMed was searched for relevant articles from 1967-2018 in the English language. Search terms include combinations of “cutaneous,” “skin,” “marginal zone lymphoma,” “MALT lymphoma,”

"immunocytoma," "amyloidoma," "plasmacytoma," "follicular lymphoid hyperplasia," "follicle center lymphoma," "diffuse large B-cell lymphoma," "large B-cell lymphoma, leg type," "chronic lymphocytic leukemia/small lymphocytic lymphoma," "multiple myeloma," "plasmablastic lymphoma," "IgG4," "Zoon's balanitis/vulvitis," "light chain," "in situ hybridization," "cutaneous pseudolymphoma," "skin pseudolymphoma," "cutaneous plasmacytosis," "kappa," "lambda," and "immunohistochemistry." In the absence of larger studies, case series of n≥3 were included.

Results

63 relevant articles assessing kappa and lambda IHC or ISH in the evaluation of an atypical cutaneous or mucosal lymphoid infiltrate were identified (Table 1, Supplementary Table).[5,9-18,22-73] 44 papers evaluated IHC exclusively,[10,11,13,15,17,22-29,31,32,34,35,37,40,42,45,46,48-50,52-55,57-69,71-73] while 9 papers evaluated ISH exclusively,[9,16,18,30,43,44,47,70,73] and 10 papers examined both IHC and ISH.[5,12,14,33,36,38,39,41,51,56] Two studies examined frozen tissue only,[58,65] 5 studies used frozen and FFPE tissue,[25,35,49,61,62] one study used formalin- or glutaraldehyde-fixed, paraffin-embedded tissue,[28] one study used formalin or B5-fixed, paraffin-embedded tissue,[50] one study used formalin or Zenker's fixed paraffin-embedded tissue,[71] one study used formalin and B5-fixed paraffin-embedded tissue and frozen tissue,[67] three studies did not specify fixation,[47,70,73] and the remainder utilized FFPE tissue.[5,9-18,22-24,26,27,29-34,36-48,51-57,59,60,64,66,68,69,72]

Most studies examined marginal zone lymphomas (MZL) of skin and mucosa (i.e. extranodal marginal zone lymphomas of mucosa associated lymphoid tissue), either alone or in combination with other lymphomas or atypical lymphoid infiltrates (39 papers; Figure 1A-F).[5,9,11,13,14,16-18,22-24,28-33,35,38,39,41,43,44,49,50,52-54,58,60-64,66,68,69,72,73] 16 papers exclusively examined primary cutaneous marginal zone lymphoma with kappa and lambda IHC/ISH, including lesions termed immunocytomas, amyloidomas, primary cutaneous plasmacytomas and cutaneous follicular lymphoid hyperplasia with monotypic plasma cells.[13,14,18,24,29,30,32,43,44,52-54,66,68,69,73] Other papers focused on extranodal marginal zone secondarily involving the skin or mucosa and other sites,[9] or a combination of primary and secondary MZLs.[11,23,24,28,31,50,62-64] The MZLs studied included plasma cell rich variants, in which plasma cells made up 50% or more of neoplastic cells.[11,18,23,24,28,31,35,41,43,50,52,54,62,63] Other lymphomas examined using kappa and lambda IHC or ISH included the relatively skin specific entities follicle center lymphoma (FCL)[5,16,23,28,37,41,56,61,64-66] and primary cutaneous diffuse large B-cell lymphoma, leg type (DLBCL-LT).[5,22,37,41,61] One study examined primary and secondary cutaneous "T-cell-rich B-cell lymphomas."[67] Secondary cutaneous involvement by systemic B-cell lymphomas were also studied, included chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),[5,16,25,26,39,55] mantle cell lymphoma (MCL),[23,28] lymphoplasmacytic lymphoma,[23,28] plasmablastic lymphoma,[41] "immunoblastic" lymphoma,[41,72] and cutaneous B-cell lymphoma not further classified.[66] Some studies included diffuse large B-cell lymphomas that were not fully subtyped.[16,23,28] One paper examined a variety of systemic plasma cell dyscrasias in the skin (multiple myeloma, monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, and polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS)).[42] Seven other papers examined cutaneous involvement by multiple myeloma.[5,15,28,41,48,70,71] Eleven papers examined kappa and lambda restriction in mucosal

lesions, including oral, ocular and genital mucosa.[9,10,23,28,33,35,45,50,56,58,60] When histopathologic features were fully described, plasma cells were inconspicuous to absent in FCL,[28,37,41] MCL,[28] DLBCL,[37,41] and most cases of CLL/SLL,[25,26,39,55] and light chain restriction was recognized in some cases by weak staining of B cells.[31,41] Non-neoplastic infiltrates examined using kappa and lambda IHC and ISH included reactive lymphoid hyperplasia (cutaneous lymphoid hyperplasia, atypical lymphoid hyperplasia, "lymphocytoma cutis"),[5,16,17,22,24,27,28,41,45,56,60,64,72], cutaneous plasmacytosis,[12,34,36,40,46] connective tissue disease,[9,47,72] IgG4-related disease,[33,51] acrodermatitis chronic atrophicans,[57] Zoon's balanitis,[10] allergic dermatitis,[72] rosacea,[72] lichen planus,[72] syphilis,[72] and plasma-cell-rich infiltrates around epithelial dysplasias and neoplasias (Figure 2A-F).[72] The clinical impression was not included in many studies.[5,12,14,16,23,28-35,37,38,41,43,46,47,49-52,56-58,60,65-67,69-73]

Discussion

Cutaneous lymphomas are often diagnostically challenging because they show significant clinical and histopathological overlap with reactive processes and usually contain numerous reactive inflammatory cells.[21] Further complicating matters, some regions of the body, such as the ocular, oral and genital mucosa and mucocutaneous junctions, normally have increased numbers of reactive lymphoid and plasma cells.[10] Moreover, overt lymphoma, especially MZL, may progress from pre-existing, non-neoplastic lymphoid infiltrates.[9,33,53,58,74] Small biopsy size, crush artifact, fixation issues, and distortion of lymphoid architecture by collagen and adnexal structures are common complications and may further hamper interpretation. Often a combination of clinical, morphologic, immunophenotypic and genetic findings are necessary to render the appropriate diagnosis. Kappa and lambda ISH and IHC are often used in the evaluation of an atypical cutaneous lymphoid infiltrate, as light chain restriction in B cells or plasma cells is highly suggestive of a clonal neoplastic process.

B cells express surface light chain starting in the pre-B-cell stage. As they mature to plasma cells, B cells increase production of light chain mRNA. Plasma cells have abundant cytoplasmic light chain, but lose surface light chain. ISH detects *KAPPA* and *LAMBDA* mRNA within the cytoplasm of plasma cells and some B cells. In contrast, IHC recognizes cellular and extracellular kappa and lambda proteins. Flow cytometry (FC) also detects light chain restriction. It is often used to detect surface light chain, but can be used to detect cytoplasmic light chain following a permeabilization procedure. ISH has been found to be superior to IHC in some studies.[6,8] In the paper by Rimsza et al., for example, the sensitivity of chromogenic ISH (CISH) was found to be 89%, while specificity was found to be 99%, when flow cytometry or IHC was used as a reference method.[6] In some conditions, IHC may display high background due to serum light chains, reactivity with follicular dendritic cells, or non-specific staining, and may show low sensitivity for one or both light chains.[1,7,8,41] In contrast, many laboratories find that ISH is less likely to show background as it detects intracellular components, and has been reported to be more likely to recognize light chain restriction within B cells, depending on their stage of differentiation.[6,8] While ISH may be better at detecting light chain restriction within B cells than IHC, similar to IHC, ISH is best able to detect light chain restriction in plasma cells and cells with plasmacytic differentiation,[41] though newer techniques such as bright field ISH may help in the detection of light chain

restriction in B cells.[16] Practically speaking, laboratories may find they have better outcomes with IHC or ISH based upon a variety of factors, including experience and platform, among other causes. Furthermore, ISH is ideally performed with separate positive and negative controls on the tissue of interest, which can be difficult for small biopsies.

In the papers evaluated here, both kappa and lambda IHC and ISH were useful in the evaluation of atypical cutaneous lymphoid infiltrates. Detection of light chain restriction in plasma cells or B cells supported a clonal B-cell and/or plasma cell population and a neoplastic process over an atypical reactive process. This was especially true for neoplasms with plasmacytic differentiation; however, some lymphomas without overt plasmacytic differentiation, including a subset of CLL/SLL,[5,25,26,55] FCL[16,28,37,41,61,64,65] and DLBCL[5,16,37,41] also revealed light chain restriction. While plasmacytic differentiation is expected for plasma cell neoplasms, lymphoplasmacytic lymphoma and many MZLs, CLL/SLL may show plasmacytic differentiation,[25,39] and a variety of other B-cell lymphomas rarely show an associated neoplastic plasma cell component.[75]

A handful of studies examined kappa and lambda IHC and ISH in cutaneous involvement by a plasma cell dyscrasia. Magro et al. examined scleroderma-like tissue reactions in 10 patients with a preceding, concurrent or subsequent diagnosis of plasma cell dyscrasia, including monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenstrom macroglobulimemia, and POEMS syndrome.[42] Patients presented with eosinophilic fasciitis (5 cases), morphea (3 cases) or systemic scleroderma (2 cases). In 5 cases, plasma cells were light chain restricted; none of the cases showed an atypical distribution or increase in number of plasma cells compared to typical eosinophilic fasciitis and morphea. Seven other studies examined cutaneous involvement by multiple myeloma.[5,15,28,41,48,70,71] Papers with full histopathologic descriptions reported nodules to sheets of plasma cells. With the exception of three cases that could not be determined, all cases with reported kappa and lambda IHC or ISH were light chain restricted. In comparison to MZLs and other types of B-cell lymphomas and lymphoproliferative disorders, little has been examined in the realm of cutaneous plasma cell dyscrasias with respect to light chain restriction. Nonetheless, the available studies highlight that examination of kappa and lambda light chains by IHC and ISH are useful in the evaluation of cutaneous plasma cell dyscrasias and associated scleroderma-like tissue reactions.

The kappa to lambda ratio used to support a monoclonal process and diagnosis of lymphoma varied significantly, with some authors using a kappa to lambda ratio that overlapped with normal ratios (kappa:lambda >2.5-3[33,41]or lambda:kappa ≥1[41]) and others using a more pronounced ratio (kappa:lambda ≥8-10[8-15,72] or lambda:kappa >3-10[8,10-18,72]). Still, other authors used an intermediate range (kappa:lambda >5[5,16-18] lambda:kappa >1.6-2:1[5,9,33]). Unfortunately, many studies do not specify the kappa and lambda ratio that was used to determine light chain restriction.[23-26,28-32,34-36,38-40,42-45,47-55,57-59,62-66,68-71,73] Complicating matters, universally accepted standards for kappa to lambda ratios that signify light chain restriction and monotypia have not been established.

While this review focuses on the utility of IHC and ISH for kappa and lambda light chains, these tests must be interpreted in the context of the patient's clinical and other histopathological findings. These studies are only one factor in arriving at the correct diagnosis. Reactive processes have rarely been

reported to show light chain restriction. Therefore, light chain restriction may not be unequivocally diagnostic of lymphoma.[1,9,16,20,27,33,41] Some of these reported cases, however, are described with a kappa: lambda ratio within normal limits,[33,41] and some may represent a lymphoma in evolution.[9,33,41] For example, Sjogren's syndrome may rarely display light chain restricted B cells and plasma cells without the development of lymphoma.[9] Similarly, cutaneous plasmacytosis has been reported to rarely show light chain restriction.[12] These cases may represent an exaggeration of normal B cell selection that occurs in response to an immune stimulus.[20] Unusual B-cell lymphomas or plasma cell neoplasms may include separate kappa and lambda-positive clones that mimic a normal kappa to lambda ratio.[30,76,77] Conversely, neoplastic B cells and plasma cells may not show light chain restriction by IHC or ISH.[11,15,32,35,50,61] In some challenging cases, additional studies may be needed to assess clonality.[33,41]

FC is of limited utility for small skin tumors. However, it is generally an important tool in the evaluation of hematopoietic neoplasms and can also be used to evaluate light chain restriction in atypical cutaneous lymphoid infiltrates. FC detects light chains on the surface and/or in the cytoplasm of B cells and detects cytoplasmic light chains in plasma cells. Examination of cytoplasmic proteins requires a permeabilization procedure. FC can be performed on skin biopsies, including punch biopsies and requires fairly rapid transport of fresh tissue to the flow cytometry laboratory (within 4-6 hours) in Roswell Park Memorial Institute (RPMI) media. Gentle mincing/grinding of the tissue followed by filtration provide optimal results.[5,64,76] Cells are then combined with fluorescently-labelled kappa and lambda antibodies and the specimen is examined using the flow cytometer. If there are sufficient cells, FC allows the assessment of additional antigens on a given cell and it also assists in the recognition of dim antigen expression. It is reported to be more sensitive than IHC/ISH[5,6,50,64,76] and IgH gene rearrangement studies[5,64,76] at recognizing a clonal B-cell population. In comparison to IHC/ISH with a sensitivity of 37-55% and IgH gene rearrangement studies with a sensitivity of 39-43%, FC has a sensitivity of 68-100%.[5,64,76] However, FC has some drawbacks. It requires fresh tissue, special RPMI media, and rapid processing, and it does not include morphologic examination. A second biopsy is therefore often required for subclassification of the lymphoma. Sparse lymphoma infiltrates may not have sufficient neoplastic cells for FC studies,[5,64] and large, fragile cells as seen in DLBCL or FCL may not survive processing.[5] As cutaneous marginal zone lymphomas may show restricted plasma cells only in the deepest portion of the lesion,[13] flow cytometry theoretically could give false negative results in superficial biopsies. Surface light chain assessment is not optimal for assessing plasma cells, and plasma cells may be underrepresented on flow cytometry, complicating evaluation of lymphomas with significant plasmacytic differentiation.[5] Finally, FC laboratories vary in familiarity and technique in the evaluation of skin biopsies.

Gene rearrangement studies examining *IGH* or *IGK/IGL* are also helpful in the evaluation of a possible cutaneous lymphoma or plasma cell neoplasm. This topic has recently been reviewed.[77] In summary, these studies help to support a diagnosis of lymphoma, but may be limited by insufficient or low-quality DNA, variability in the annealing of primer sets to the target sequences, somatic hypermutation, clonal heterogeneity, or variability/difficulty in the interpretation of monoclonal peaks.[77-80] Consequently, monoclonal gene rearrangements may be found in lesions that do not meet other clinical or histopathologic features of a lymphoma,[5,17,27,40,64] and neoplastic B-cell and plasma cell populations may

not be recognized as monoclonal. These studies may miss clonal B-cell populations in as many as 50% of cases.[81] Gene rearrangement studies are best interpreted in the context of a case assessed in its entirety.

Next generation sequencing (NGS) is emerging as a tool for detection of clonal immunoglobulin light chain gene rearrangement studies.[79] Although more studies are needed, this technique may be more sensitive at recognizing a monoclonal B-cell population, even in low density, poor quality samples. In addition, NGS can be used to simultaneously assess multiple proteins important for diagnosis or prognosis.[77,80]

In summary, there are several well-supported scenarios for the use of IHC and ISH for kappa and lambda light chains in the literature; however, important gaps in our knowledge remain. Specifically, a standard kappa:lambda threshold for determining light chain restriction in cutaneous lesions is not defined. There is an unclear relationship between light chain restriction (i.e. monotypism) and monoclonality assessed by gene rearrangement studies, although these often co-occurred in the few studies that examined both. Finally, there is a lack of guidance on the sequential or concurrent utility of kappa/lambda light chain expression by IHC/ISH, flow cytometry, *IGH* and *IGK/IGL* gene rearrangement or NGS in the diagnosis and evaluation of cutaneous lymphoid infiltrates that are concerning for lymphoma. Upcoming recommendations from the ASDP AUC committee will be published separately and aim to provide guidance on the use of IHC and ISH to detect light chain restriction and utility of these tests in diagnostic dermatopathology. Importantly, there are pitfalls in the clinical, histopathologic, immunophenotypic, and genetic analysis of these cases, and accurate diagnosis relies upon a thorough assessment of the features of the case as a whole.

References

1. Weiss LM, Loera S, Bacchi CE. Immunoglobulin light chain immunohistochemistry revisited, with emphasis on reactive follicular hyperplasia versus follicular lymphoma. *Appl Immunohistochem Mol Morphol.* 2010;18(3):199-205.
2. Taylor CR, Burns J. The demonstration of plasma cells and other immunoglobulin-containing cells in formalin-fixed, paraffin-embedded tissues using peroxidase-labelled antibody. *J Clin Pathol.* 1974;27(1):14-20.
3. Marshall-Taylor CE, Cartun RW, Mandich D, DiGiuseppe JA. Immunohistochemical detection of immunoglobulin light chain expression in B-cell non-Hodgkin lymphomas using formalin-fixed, paraffin-embedded tissues and a heat-induced epitope retrieval technique. *Appl Immunohistochem Mol Morphol.* 2002;10(3):258-262.
4. Ashton-Key M, Jessup E, Isaacson PG. Immunoglobulin light chain staining in paraffin-embedded tissue using a heat mediated epitope retrieval method. *Histopathology.* 1996;29(6):525-531.
5. Schafernak KT, Variakojis D, Goolsby CL, et al. Clonality assessment of cutaneous B-cell lymphoid proliferations: a comparison of flow cytometry immunophenotyping, molecular studies, and immunohistochemistry/in situ hybridization and review of the literature. *Am J Dermatopathol.* 2014;36(10):781-795.
6. Rimsza LM, Day WA, McGinn S, et al. Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas. *Diagn Pathol.* 2014;9:144.
7. Weiss LM, Movahed LA, Chen YY, et al. Detection of immunoglobulin light-chain mRNA in lymphoid tissues using a practical in situ hybridization method. *Am J Pathol.* 1990;137(4):979-988.
8. Beck RC, Tubbs RR, Hussein M, Pettay J, Hsi ED. Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. *Diagn Mol Pathol.* 2003;12(1):14-20.
9. Speight PM, Jordan R, Colloby P, Nandha H, Pringle JH. Early detection of lymphomas in Sjogren's syndrome by in situ hybridisation for kappa and lambda light chain mRNA in labial salivary glands. *Eur J Cancer B Oral Oncol.* 1994;30B(4):244-247.
10. Toonstra J, van Wichen DF. Immunohistochemical characterization of plasma cells in Zoon's balanoposthitis and (pre)malignant skin lesions. *Dermatologica.* 1986;172(2):77-81.
11. Brenner I, Roth S, Puppe B, Wobser M, Rosenwald A, Geissinger E. Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression. *Mod Pathol.* 2013;26(12):1568-1576.
12. Honda R, Cerroni L, Tanikawa A, Ebihara T, Amagai M, Ishiko A. Cutaneous plasmacytosis: report of 6 cases with or without systemic involvement. *J Am Acad Dermatol.* 2013;68(6):978-985.
13. Hardin JC, Barrows B, Duff JI, et al. Light chain restriction confined to lower portions of cutaneous lymphocytic proliferations: a potential diagnostic pitfall. *J Cutan Pathol.* 2014;41(12):978-980.

14. Walsh NM, Lano IM, Green P, et al. AL Amyloidoma of the skin/subcutis: cutaneous amyloidosis, plasma cell dyscrasia or a manifestation of primary cutaneous marginal zone lymphoma? *Am J Surg Pathol.* 2017;41(8):1069-1076.
15. Bayer-Garner IB, Prieto VG, Smoller BR. Detection of clonality with kappa and lambda immunohistochemical analysis in cutaneous plasmacytomas. *Arch Pathol Lab Med.* 2004;128(6):645-648.
16. Minca EC, Wang H, Wang Z, et al. Detection of immunoglobulin light-chain restriction in cutaneous B-cell lymphomas by ultrasensitive bright-field mRNA in situ hybridization. *J Cutan Pathol.* 2015;42(2):82-89.
17. Ceballos KM, Gascoyne RD, Martinka M, Trotter MJ. Heavy multinodular cutaneous lymphoid infiltrates: clinicopathologic features and B-cell clonality. *J Cutan Pathol.* 2002;29(3):159-167.
18. Kempf W, Kazakov DV, Buechner SA, et al. Primary cutaneous marginal zone lymphoma in children: a report of 3 cases and review of the literature. *Am J Dermatopathol.* 2014;36(8):661-666.
19. Bain VG, Bain GO. Lymphocyte populations with abnormal kappa:lambda ratios in reactive lymphoid hyperplasia. *J Surg Oncol.* 1985;29(4):227-230.
20. Kroft SH. Monoclones, monotypes, and neoplasia pitfalls in lymphoma diagnosis. *Am J Clin Pathol.* 2004;121(4):457-459.
21. Mitteldorf C, Kempf W. Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification. *J Cutan Pathol.* 2020;47(1):76-97.
22. Arai E, Shimizu M, Hirose T. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis. *Hum Pathol.* 2005;36(5):505-511.
23. Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Graff A, Buchen R, Witschel H. Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. *Br J Ophthalmol.* 2001;85(1):63-69.
24. Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. *Am J Surg Pathol.* 1999;23(1):88-96.
25. Cerroni L, Zenahlik P, Hofler G, Kaddu S, Smolle J, Kerl H. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologic and prognostic study of 42 patients. *Am J Surg Pathol.* 1996;20(8):1000-1010.
26. Cerroni L, Zenahlik P, Kerl H. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia arising at the site of herpes zoster and herpes simplex scars. *Cancer.* 1995;76(1):26-31.
27. Colli C, Leinweber B, Mullegger R, Chott A, Kerl H, Cerroni L. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. *J Cutan Pathol.* 2004;31(3):232-240.
28. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. *Ophthalmology.* 1998;105(8):1430-1441.

29. Dangien A, Beylot-Barry M, Battistella M, et al. Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin. *Br J Dermatol.* 2019;181(3):607-609.
30. De Souza A, Ferry JA, Burghart DR, et al. IgG4 Expression in primary cutaneous marginal zone lymphoma: a multicenter study. *Appl Immunohistochem Mol Morphol.* 2018;26(7):462-467.
31. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. *Am J Surg Pathol.* 2010;34(12):1830-1841.
32. Frings VG, Roding K, Strate A, et al. Paraproteinaemia in primary cutaneous marginal zone lymphoma. *Acta Derm Venereol.* 2018;98(10):956-962.
33. Go H, Kim JE, Kim YA, et al. Ocular adnexal IgG4-related disease: comparative analysis with mucosa-associated lymphoid tissue lymphoma and other chronic inflammatory conditions. *Histopathology.* 2012;60(2):296-312.
34. Han XD, Lee SSJ, Tan SH, et al. Cutaneous plasmacytosis: a clinicopathologic study of a series of cases and their treatment outcomes. *Am J Dermatopathol.* 2018;40(1):36-42.
35. Hara Y, Nakamura N, Kuze T, et al. Immunoglobulin heavy chain gene analysis of ocular adnexal extranodal marginal zone B-cell lymphoma. *Invest Ophthalmol Vis Sci.* 2001;42(11):2450-2457.
36. Jayaraman AG, Cesca C, Kohler S. Cutaneous plasmacytosis: A report of five cases with immunohistochemical evaluation for HHV-8 expression. *Am J Dermatopathol.* 2006;28(2):93-98.
37. Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. *Am J Surg Pathol.* 2010;34(7):1043-1048.
38. LeBoit PE, McNutt NS, Reed JA, Jacobson M, Weiss LM. Primary cutaneous immunocytoma. A B-cell lymphoma that can easily be mistaken for cutaneous lymphoid hyperplasia. *Am J Surg Pathol.* 1994;18(10):969-978.
39. Levin C, Mirzamani N, Zwerner J, Kim Y, Schwartz EJ, Sundram U. A comparative analysis of cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia. *Am J Dermatopathol.* 2012;34(1):18-23.
40. Lu PH, Shih LY, Yang CH, Kuo TT. Cutaneous plasmacytosis: a clinicopathologic study of 12 cases in Taiwan revealing heterogeneous underlying causes. *Int J Dermatol.* 2015;54(10):1132-1137.
41. Magro C, Crowson AN, Porcu P, Nuovo GJ. Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. *J Cutan Pathol.* 2003;30(8):504-511.
42. Magro CM, Iwenofu H, Nuovo GJ. Paraneoplastic scleroderma-like tissue reactions in the setting of an underlying plasma cell dyscrasia: a report of 10 cases. *Am J Dermatopathol.* 2013;35(5):561-568.
43. Magro CM, Porcu P, Ahmad N, Klinger D, Crowson AN, Nuovo G. Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases. *Appl Immunohistochem Mol Morphol.* 2004;12(3):216-224.
44. Magro CM, Yang A, Fraga G. Blastic marginal zone lymphoma: a clinical and pathological study of 8 cases and review of the literature. *Am J Dermatopathol.* 2013;35(3):319-326.

45. Menasce LP, Shanks JH, Banerjee SS, Harris M. Follicular lymphoid hyperplasia of the hard palate and oral mucosa: report of three cases and a review of the literature. *Histopathology.* 2001;39(4):353-358.
46. Miyagawa-Hayashino A, Matsumura Y, Kawakami F, et al. High ratio of IgG4-positive plasma cell infiltration in cutaneous plasmacytosis--is this a cutaneous manifestation of IgG4-related disease? *Hum Pathol.* 2009;40(9):1269-1277.
47. Pereira A, Ferrara G, Calamaro P, et al. The histopathological spectrum of pseudolymphomatous infiltrates in cutaneous lupus erythematosus. *Am J Dermatopathol.* 2018;40(4):247-253.
48. Requena L, Kutzner H, Palmedo G, et al. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. *Arch Dermatol.* 2003;139(4):475-486.
49. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. *Histopathology.* 1993;23(2):117-125.
50. Ruiz A, Reischl U, Swerdlow SH, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. *Am J Surg Pathol.* 2007;31(5):792-802.
51. Sato Y, Takeuchi M, Takata K, et al. Clinicopathologic analysis of IgG4-related skin disease. *Mod Pathol.* 2013;26(4):523-532.
52. Schmid U, Eckert F, Griesser H, et al. Cutaneous follicular lymphoid hyperplasia with monotypic plasma cells. A clinicopathologic study of 18 patients. *Am J Surg Pathol.* 1995;19(1):12-20.
53. Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. *Br J Dermatol.* 2002;147(6):1147-1158.
54. Servitje O, Muniesa C, Benavente Y, et al. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. *J Am Acad Dermatol.* 2013;69(3):357-365.
55. Smoller BR, Warnke RA. Cutaneous infiltrate of chronic lymphocytic leukemia and relationship to primary cutaneous epithelial neoplasms. *J Cutan Pathol.* 1998;25(3):160-164.
56. Stacy RC, Jakobiec FA, Schoenfield L, Singh AD. Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa. *Am J Ophthalmol.* 2010;150(3):412-426 e411.
57. Tee SI, Martinez-Escaname M, Zuriel D, et al. Acrodermatitis chronica atrophicans with pseudolymphomatous infiltrates. *Am J Dermatopathol.* 2013;35(3):338-342.
58. van Maldegem F, Wormhoudt TA, Mulder MM, et al. Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment. *Leukemia.* 2012;26(7):1647-1653.
59. Yamada K, Hamaguchi Y, Saeki T, et al. Investigations of IgG4-related disease involving the skin. *Mod Rheumatol.* 2013;23(5):986-993.
60. Zhu J, Wei RL, Pi YL, Guo Q. Significance of Bcl10 gene mutations in the clinical diagnosis of MALT-type ocular adnexal lymphoma in the Chinese population. *Genet Mol Res.* 2013;12(2):1194-1204.

61. Bergman R, Kurtin PJ, Gibson LE, Hull PR, Kimlinger TK, Schroeter AL. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. *Arch Dermatol.* 2001;137(4):432-439.
62. Bailey EM, Ferry JA, Harris NL, Mihm MC, Jr., Jacobson JO, Duncan LM. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. *Am J Surg Pathol.* 1996;20(8):1011-1023.
63. Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM. Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. *Am J Clin Pathol.* 1991;96(6):738-745.
64. Wu JM, Vonderheid E, Gocke CD, Moresi JM, Liegeois N, Borowitz MJ. Flow cytometry of lesional skin enhances the evaluation of cutaneous B-cell lymphomas. *J Cutan Pathol.* 2012;39(10):918-928.
65. Garcia CF, Weiss LM, Warnke RA, Wood GS. Cutaneous follicular lymphoma. *Am J Surg Pathol.* 1986;10(7):454-463.
66. Yang B, Tubbs RR, Finn W, Carlson A, Pettay J, Hsi ED. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. *Am J Surg Pathol.* 2000;24(5):694-702.
67. Sander CA, Kaudewitz P, Kutzner H, et al. T-cell-rich B-cell lymphoma presenting in skin. A clinicopathologic analysis of six cases. *J Cutan Pathol.* 1996;23(2):101-108.
68. Tomaszewski MM, Abbondanzo SL, Lupton GP. Extranodal marginal zone B-cell lymphoma of the skin: a morphologic and immunophenotypic study of 11 cases. *Am J Dermatopathol.* 2000;22(3):205-211.
69. Cerroni L, Signoretti S, Hofler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. *Am J Surg Pathol.* 1997;21(11):1307-1315.
70. Woo YR, Kim JS, Lim JH, et al. Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. *J Am Acad Dermatol.* 2018;78(3):471-478 e474.
71. Patterson JW, Parsons JM, White RM, Fitzpatrick JE, Kohout-Dutz E. Cutaneous involvement of multiple myeloma and extramedullary plasmacytoma. *J Am Acad Dermatol.* 1988;19(5 Pt 1):879-890.
72. Burg G, Kerl H, Kaudewitz P, Braun-Falco O, Mason DY. Immunoenzymatic typing of lymphoplasmacytoid skin infiltrates. *J Dermatol Surg Oncol.* 1984;10(4):284-290.
73. Geyer JT, Ferry JA, Longtine JA, Flotte TJ, Harris NL, Zukerberg LR. Characteristics of cutaneous marginal zone lymphomas with marked plasmacytic differentiation and a T cell-rich background. *Am J Clin Pathol.* 2010;133(1):59-69.
74. Swerdlow SH, Campo E, Harris NL, et al., eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.* Lyon, France: IARC; 2017.
75. Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. *Virchows Arch.* 2016;468(3):259-275.
76. Wu H, Smith M, Millenson MM, et al. Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions. *J Invest Dermatol.* 2003;121(6):1522-1530.

77. Comfere N, Sundram U, Hurley MY, Swick B. Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders. *J Cutan Pathol.* 2018;45(1):39-47.
78. Raess PW, Bagg A. The role of molecular pathology in the diagnosis of cutaneous lymphomas. *Patholog Res Int.* 2012;2012:913523.
79. Scheijen B, Meijers RWJ, Rijntjes J, et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. *Leukemia.* 2019;33(9):2227-2240.
80. Jeon YK, Yoon SO, Paik JH, et al. Molecular testing of lymphoproliferative disorders: current status and perspectives. *J Pathol Transl Med.* 2017;51(3):224-241.
81. Lukowsky A, Marchwat M, Sterry W, Gellrich S. Evaluation of B-cell clonality in archival skin biopsy samples of cutaneous B-cell lymphoma by immunoglobulin heavy chain gene polymerase chain reaction. *Leuk Lymphoma.* 2006;47(3):487-493.

Figure Legends:

Figure 1: Primary cutaneous marginal zone lymphoma. Sections show a dense lymphoid infiltrate with a grenz zone and numerous plasma cells (Figure 1A, B, 100X, 200X). IHC for kappa reveals numerous kappa-positive cells (Figure 1C, 100X), while IHC for lambda reveals few scattered cells (Figure 1D, 100X) with a kappa:lambda of >10:1. Similarly, kappa ISH marks numerous cells (Figure 1E, 100X), while lambda ISH reveals rare cells (Figure 1F, 100X).

Figure 2: A dense, reactive infiltrate of plasma cells. Sections show psoriasiform epidermal hyperplasia with numerous associated plasma cells (Figure 2A,B, 40X, 100X). Kappa IHC reveals kappa-positive cells (Figure 2B, 100X) and lambda IHC shows slightly fewer lambda-positive cells (Figure 2C, 100X) for a kappa:lambda of approximately 2:1. ISH similarly shows a slight predominance of kappa (Figure 2D, 100X) compared to lambda (Figure 2E, 100X).

Table Legends:

Table 1: Summary of articles assessing kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of an atypical cutaneous lymphoid infiltrate.

Supplementary Table: Synopsis of articles from 1967-2018 assessing kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) in cutaneous lymphoid infiltrates in the English language. CLH – cutaneous lymphoid hyperplasia; RLH – reactive lymphoid hyperplasia; PC DLBCL – primary cutaneous diffuse large B-cell lymphoma; DLBCL – diffuse large B-cell lymphoma; PCDLBCL-LT – primary cutaneous diffuse large B-cell lymphoma, leg type; LBCL – large B-cell lymphoma, PCDLBCL – primary cutaneous diffuse large B-cell lymphoma; MZL – marginal zone lymphoma; PCMZL – primary cutaneous marginal zone lymphoma; EMZL – extranodal marginal zone lymphoma; CMZL – cutaneous marginal zone lymphoma; SCMZL – secondary cutaneous MZL; CBCL-cutaneous B-cell lymphoma; FCL – follicle center lymphoma; PCFCL – primary cutaneous follicle center

lymphoma; SCFCL – secondary cutaneous follicle center lymphoma; FL – follicular lymphoma; CLL – chronic lymphocytic leukemia; SCSCL – secondary cutaneous small cell lymphoma, SLL – small lymphocytic lymphoma; POEMS – polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; MM – multiple myeloma; PTCL, NOS – peripheral T-cell lymphoma, not otherwise specified; MF – mycosis fungoides; EBV – Epstein Barr Virus; HHV8 – Human Herpes Virus 8; FFPE – formalin fixed, paraffin embedded; FS – frozen section; PCR-polymerase chain reaction; IgH – immunoglobulin heavy chain; BRISH – bright field RNA in situ hybridization, mRNA – messenger ribonucleic acid; RPR – rapid plasma reagin; ANA – antinuclear antibody; HIV – human immunodeficiency virus.

Table 1:

Total Number of Articles	63
Breakdown by IHC and/or ISH	
IHC	44
ISH	9
IHC and ISH	10
Breakdown by specimen processing	
Frozen	2
Formalin fixed paraffin embedded (FFPE)	49
Frozen and FFPE	5
FFPE and glutaraldehyde fixed paraffin embedded	1
FFPR and Zenker's fixed paraffin embedded	1
FFPE and B5 fixed paraffin embedded	1
FFPE and B5 fixed paraffin embedded and frozen	1
Not specified	3
Breakdown by Diagnosis	
Cutaneous B-cell lymphoma, not further specified	2
Marginal zone lymphoma	39
Primary Cutaneous marginal zone lymphoma*	26
Follicle center lymphoma	11
Diffuse large B-cell lymphoma	8
Diffuse large B-cell lymphoma, leg type	5
Chronic lymphocytic leukemia/small lymphocytic lymphoma	7
Mantle Cell Lymphoma	2

Lymphoplasmacytic lymphoma	2
Plasmablastic lymphoma	1
Plasma cell dyscrasias, including plasmacytoma	8
Multiple myeloma	7
Lymphoid hyperplasia, cutaneous and mucosal	13
Cutaneous plasmacytosis	5
Connective tissue disease	3
IgG4-related disease	2
Acrodermatitis chronica atrophicans	1
Zoon's balanitis	1
Allergic dermatitis	1
Rosacea	1
Lichen planus	1
Syphilis	1
Plasma cell rich infiltrates around epithelial dysplasia/neoplasia	1
Secondary cutaneous B-cell lymphoma (not specified above)	5

* Includes lesions termed immunocytomas, amyloidomas, primary cutaneous plasmacytomas and cutaneous follicular lymphoid hyperplasia with monotypic plasma cells examined alone or in combination with other lymphomas



CUP_13858_Figure 1_CUP-R1-387-2020 copy.tif



CUP_13858_Figure 2_CUP-R1-387-2020_1 copy.tif

Table 1:

Total Number of Articles	63
Breakdown by IHC and/or ISH	
IHC	44
ISH	9
IHC and ISH	10
Breakdown by specimen processing	
Frozen	2
Formalin fixed paraffin embedded (FFPE)	49
Frozen and FFPE	5
FFPE and glutaraldehyde fixed paraffin embedded	1
FFPR and Zenker's fixed paraffin embedded	1
FFPE and B5 fixed paraffin embedded	1
FFPE and B5 fixed paraffin embedded and frozen	1
Not specified	3
Breakdown by Diagnosis	
Cutaneous B-cell lymphoma, not further specified	2
Marginal zone lymphoma	39
Primary Cutaneous marginal zone lymphoma*	26
Follicle center lymphoma	11
Diffuse large B-cell lymphoma	8
Diffuse large B-cell lymphoma, leg type	5
Chronic lymphocytic leukemia/small lymphocytic lymphoma	7
Mantle Cell Lymphoma	2
Lymphoplasmacytic lymphoma	2
Plasmablastic lymphoma	1
Plasma cell dyscrasias, including plasmacytoma	8
Multiple myeloma	7
Lymphoid hyperplasia, cutaneous and mucosal	13
Cutaneous plasmacytosis	5
Connective tissue disease	3
IgG4-related disease	2
Acrodermatitis chronica atrophicans	1
Zoon's balanitis	1
Allergic dermatitis	1
Rosacea	1
Lichen planus	1
Syphilis	1
Plasma cell rich infiltrates around epithelial dysplasia/neoplasia	1
Secondary cutaneous B-cell lymphoma (not specified above)	5

* Includes lesions termed immunocytomas, amyloidomas, primary cutaneous plasmacytomas and cutaneous follicular lymphoid hyperplasia with monotypic plasma cells examined alone or in combination with other lymphomas

Kappa and Lambda Immunohistochemistry and In Situ Hybridization in the Evaluation of Atypical Cutaneous Lymphoid Infiltrates

Alexandra C. Hristov, M.D.[1], Nneka I. Comfere, M.D.[2], Claudia I. Vidal M.D., Ph.D.[3], and Uma Sundram M.D., Ph.D.[4]

[1]Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI

[2]Department of Dermatology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

[3]Dermatology Center of Southern Indiana, Bloomington, IN

[4]Department of Pathology, Oakland University William Beaumont School of Medicine and Beaumont Health Systems, Royal Oak, MI

Key Words: kappa, lambda, immunohistochemistry, in situ hybridization, cutaneous, lymphoma

Running Title: Kappa and lambda expression in cutaneous lymphoma

The authors have no conflicts of interest to declare.

Corresponding Author:

Alexandra C. Hristov

Associate Professor

Departments of Pathology and Dermatology

2800 Plymouth Road, Building 35

Ann Arbor, MI 48109-2800

Phone: 734-764-4460

Fax: 734-764-4690

Email: ahristov@med.umich.edu